PL2356989T3 - Trwała tabletka zawierająca pochodną 4,5-epoksymorfinanu - Google Patents
Trwała tabletka zawierająca pochodną 4,5-epoksymorfinanuInfo
- Publication number
- PL2356989T3 PL2356989T3 PL09822078T PL09822078T PL2356989T3 PL 2356989 T3 PL2356989 T3 PL 2356989T3 PL 09822078 T PL09822078 T PL 09822078T PL 09822078 T PL09822078 T PL 09822078T PL 2356989 T3 PL2356989 T3 PL 2356989T3
- Authority
- PL
- Poland
- Prior art keywords
- tablet containing
- stable tablet
- epoxymorphinan derivative
- epoxymorphinan
- derivative
- Prior art date
Links
- QONGLMDHKNFCDX-KBHMWOLSSA-N (4r,4ar,12bs)-1,2,3,4,4a,5,6,7,7a,13-decahydro-4,12-methanobenzofuro[3,2-e]isoquinoline Chemical class O1C2CCC[C@H]3[C@]4([H])NCC[C@]23C2=C1C=CC=C2C4 QONGLMDHKNFCDX-KBHMWOLSSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008274579 | 2008-10-24 | ||
| EP09822078.3A EP2356989B1 (en) | 2008-10-24 | 2009-10-23 | Stable tablet containing 4,5-epoxymorphinan derivative |
| PCT/JP2009/068228 WO2010047381A1 (ja) | 2008-10-24 | 2009-10-23 | ４，５－エポキシモルヒナン誘導体を含有する安定な錠剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2356989T3 true PL2356989T3 (pl) | 2018-07-31 |
Family
ID=42119418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL09822078T PL2356989T3 (pl) | 2008-10-24 | 2009-10-23 | Trwała tabletka zawierająca pochodną 4,5-epoksymorfinanu |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8829019B2 (pl) |
| EP (1) | EP2356989B1 (pl) |
| JP (2) | JP5648480B2 (pl) |
| KR (1) | KR101682963B1 (pl) |
| CN (1) | CN102196811B (pl) |
| AU (1) | AU2009307367B2 (pl) |
| BR (1) | BRPI0920599B1 (pl) |
| CA (1) | CA2740476C (pl) |
| DK (1) | DK2356989T3 (pl) |
| ES (1) | ES2660001T3 (pl) |
| HU (1) | HUE036876T2 (pl) |
| MX (1) | MX2011004307A (pl) |
| PL (1) | PL2356989T3 (pl) |
| PT (1) | PT2356989T (pl) |
| TR (1) | TR201802379T4 (pl) |
| WO (1) | WO2010047381A1 (pl) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012054566A2 (en) * | 2010-10-19 | 2012-04-26 | Memorial Sloan-Kettering Cancer Center | 6-amido derivatives of 4,5a-epoxymorphinans for treatment of pain |
| DK2851075T3 (da) | 2012-05-14 | 2022-01-31 | Shionogi & Co | Præparat, der indeholder 6,7-umættet -7-carbamoylmorphinanderivat |
| TWI449704B (zh) * | 2013-04-26 | 2014-08-21 | Everlight Chem Ind Corp | 嗎啡喃衍生物之結晶、其製造方法、及使用其之醫藥組成物 |
| EP4212532A3 (en) | 2015-04-30 | 2023-09-27 | Memorial Sloan Kettering Cancer Center | Mitragynine analogs and uses thereof |
| JP6858575B2 (ja) * | 2016-01-29 | 2021-04-14 | 沢井製薬株式会社 | ナルフラフィン含有口腔内崩壊錠 |
| US11185509B2 (en) | 2016-07-29 | 2021-11-30 | Toray Industries, Inc. | Solid preparation having improved light stability |
| ES2902123T3 (es) * | 2017-03-31 | 2022-03-25 | Toray Industries | Composición medicinal en tabletas que comprende nalfurafina |
| DK3761982T3 (da) | 2018-03-08 | 2025-01-02 | Victoria Link Ltd | Anvendelse af nalfurafin til behandling af demyeliniserende sygdomme |
| WO2020205735A1 (en) | 2019-03-29 | 2020-10-08 | Humanwell Pharmaceutical US | Novel morphinans useful for treating medical disorders |
| JP2022130075A (ja) * | 2021-02-25 | 2022-09-06 | フロイント産業株式会社 | 顆粒及びその製造方法、並びに錠剤 |
| US20240300939A1 (en) | 2021-06-14 | 2024-09-12 | Scorpion Therapeutics, Inc. | Urea derivatives which can be used to treat cancer |
| CN117398353B (zh) * | 2023-12-04 | 2025-04-18 | 山东新时代药业有限公司 | 一种富马酸比索洛尔片剂 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2597475A (en) * | 1949-03-09 | 1952-05-20 | Gilbert & Barker Mfg Co | Separator for removing water from gasoline |
| GB8820327D0 (en) | 1988-08-26 | 1988-09-28 | May & Baker Ltd | New compositions of matter |
| ES2121988T3 (es) | 1992-01-23 | 1998-12-16 | Toray Industries | Derivado de morfinano y uso medicinal. |
| JP3797387B2 (ja) | 1996-06-14 | 2006-07-19 | 協和醗酵工業株式会社 | 口腔内速崩壊錠 |
| WO1998035679A1 (de) | 1997-02-14 | 1998-08-20 | Gödecke Aktiengesellschaft | Stabilisierung von naloxonhydrochlorid |
| US6187782B1 (en) * | 1997-03-27 | 2001-02-13 | Toray Industries, Inc. | Morphinane derivatives and medicinal use thereof |
| PT948965E (pt) * | 1997-07-11 | 2004-08-31 | Toray Industries | Composicoes medicinais estaveis contendo um derivado de 4,5-epoximorfinano |
| US6572891B1 (en) * | 1999-10-23 | 2003-06-03 | Alkaloid Ad | Sublingual oral dosage form |
| JP3595765B2 (ja) * | 2000-09-27 | 2004-12-02 | 信越化学工業株式会社 | 低置換度ヒドロキシプロピルセルロースを含む乾式直打用基剤 |
| JP4755353B2 (ja) | 2001-04-02 | 2011-08-24 | 興和株式会社 | ビタミンｂ１製剤 |
| KR20040098660A (ko) | 2002-03-14 | 2004-11-20 | 유로-셀티크 소시에떼 아노뉨 | 날트렉손 하이드로클로라이드 조성물 |
| BR0314754A (pt) * | 2002-10-09 | 2005-07-26 | Toray Industries | Agente terapêutico ou profilático para a frequência urinária ou a incontinência urinária ou um seu sal de adição de ácido farmaceuticamente aceitável, método para terapia ou profilaxia para frequência urinária, urgência urinária ou incontinência urinária, uso de um derivado de morfina tendo um grupo heterocìclico contendo nitrogênio ou de um seu sal de adição de ácido farmaceuticamente aceitável, derivado de morfina ou um seu sal de adição de ácido farmaceuticamente aceitável, produto farmacêutico, e, composição farmacêutica |
| CA2811272C (en) | 2003-04-08 | 2016-12-20 | Progenics Pharmaceuticals, Inc. | Pharmaceutical formulations containing methylnaltrexone |
| TW200507882A (en) * | 2003-07-17 | 2005-03-01 | Kyowa Hakko Kogyo Kk | Solid formulations |
| US20080095841A1 (en) | 2004-10-06 | 2008-04-24 | Eisai R&D Management Co., Ltd. | Pharmaceutical Composition, Method for Producing the Same, and Method for Stabilizing Dihydropyridine Compound in the Pharmaceutical Composition |
| JP4567640B2 (ja) | 2005-07-29 | 2010-10-20 | 田辺三菱製薬株式会社 | 小型化塩酸サルポグレラート経口投与製剤 |
| WO2007055184A1 (ja) * | 2005-11-09 | 2007-05-18 | Toray Industries, Inc. | 機能性腸障害の治療または予防剤 |
| US8652529B2 (en) * | 2005-11-10 | 2014-02-18 | Flamel Technologies | Anti-misuse microparticulate oral pharmaceutical form |
| JP5204976B2 (ja) | 2006-01-27 | 2013-06-05 | 富山化学工業株式会社 | イグラチモドを含有する速崩壊性錠剤 |
| US20070196494A1 (en) * | 2006-02-17 | 2007-08-23 | Arnaud Grenier | Low-friability, patient-friendly orally disintegrating formulations |
| NZ574544A (en) * | 2006-08-04 | 2011-12-22 | Ethypharm Sa | Granule and orally disintegrating tablet comprising oxycodone |
| ES2829819T3 (es) * | 2010-08-26 | 2021-06-02 | Toray Industries | Composición inmunogénica |
-
2009
- 2009-10-23 CA CA2740476A patent/CA2740476C/en active Active
- 2009-10-23 MX MX2011004307A patent/MX2011004307A/es unknown
- 2009-10-23 PL PL09822078T patent/PL2356989T3/pl unknown
- 2009-10-23 PT PT98220783T patent/PT2356989T/pt unknown
- 2009-10-23 ES ES09822078.3T patent/ES2660001T3/es active Active
- 2009-10-23 KR KR1020117011543A patent/KR101682963B1/ko active Active
- 2009-10-23 EP EP09822078.3A patent/EP2356989B1/en active Active
- 2009-10-23 DK DK09822078.3T patent/DK2356989T3/en active
- 2009-10-23 WO PCT/JP2009/068228 patent/WO2010047381A1/ja not_active Ceased
- 2009-10-23 BR BRPI0920599-3A patent/BRPI0920599B1/pt active IP Right Grant
- 2009-10-23 TR TR2018/02379T patent/TR201802379T4/tr unknown
- 2009-10-23 US US13/125,726 patent/US8829019B2/en active Active
- 2009-10-23 HU HUE09822078A patent/HUE036876T2/hu unknown
- 2009-10-23 JP JP2010534846A patent/JP5648480B2/ja active Active
- 2009-10-23 AU AU2009307367A patent/AU2009307367B2/en active Active
- 2009-10-23 CN CN200980142056.8A patent/CN102196811B/zh active Active
-
2014
- 2014-03-07 JP JP2014045214A patent/JP5971272B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2010047381A1 (ja) | 2012-03-22 |
| BRPI0920599B1 (pt) | 2021-10-19 |
| HUE036876T2 (hu) | 2018-08-28 |
| TR201802379T4 (tr) | 2018-03-21 |
| MX2011004307A (es) | 2011-07-28 |
| KR20110074613A (ko) | 2011-06-30 |
| JP5648480B2 (ja) | 2015-01-07 |
| AU2009307367A1 (en) | 2010-04-29 |
| AU2009307367B2 (en) | 2015-04-23 |
| CN102196811A (zh) | 2011-09-21 |
| JP2014141503A (ja) | 2014-08-07 |
| EP2356989A1 (en) | 2011-08-17 |
| BRPI0920599A2 (pt) | 2020-12-15 |
| CN102196811B (zh) | 2014-03-19 |
| EP2356989A4 (en) | 2013-05-08 |
| PT2356989T (pt) | 2018-03-09 |
| CA2740476A1 (en) | 2010-04-29 |
| WO2010047381A1 (ja) | 2010-04-29 |
| JP5971272B2 (ja) | 2016-08-17 |
| KR101682963B1 (ko) | 2016-12-06 |
| CA2740476C (en) | 2016-04-05 |
| US20120114752A1 (en) | 2012-05-10 |
| DK2356989T3 (en) | 2018-05-07 |
| EP2356989B1 (en) | 2018-02-07 |
| US8829019B2 (en) | 2014-09-09 |
| ES2660001T3 (es) | 2018-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2356989T3 (pl) | Trwała tabletka zawierająca pochodną 4,5-epoksymorfinanu | |
| IL206765A0 (en) | 4,5-dihydro-oxazol-2-yl-amine derivatives | |
| IL201973A0 (en) | 3,3-spiroindolinone derivatives | |
| ZA201001797B (en) | 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives | |
| EP2361902A4 (en) | 4,6-DIAMINONICOTINSÄUREAMIDVERBINDUNG | |
| ZA201104317B (en) | Corn event 5307 | |
| IL213787A0 (en) | Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds | |
| IL225694A0 (en) | Compounds 6,5- dihydro-h1-pyridine-2-one | |
| IL212070A0 (en) | 7-piperidinoalkyl-3,4-dihydroquinolone derivative | |
| GB0710112D0 (en) | Tablet dispenser | |
| AP2010005345A0 (en) | Indazole derivatives. | |
| SI2356123T1 (sl) | Piro-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo(e)azuleni | |
| IL209423A0 (en) | 4,5-dihydro-oxazol-2-yl derivatives | |
| SI2513119T1 (sl) | 3,4,4a,10b-tetrahidro-1H-tiopirano-(4,3-c)izokinolinski derivati | |
| PL394605A1 (pl) | Trwała złożona kompozycja farmaceutyczna | |
| EP2202231A4 (en) | 2,3-DIHYDROIMINOISOINDOLE DERIVATIVE | |
| ZA201005346B (en) | 3,8-diaminotetrahydroquinoline derivative | |
| ZA201103374B (en) | Shelf stable capsules | |
| IL201444A0 (en) | New 4, 8 - diphenyl - polyazanaphthalene derivatives | |
| IL213762A0 (en) | 1,1,1-trifluoro-2-hydroxypropyl compounds | |
| GB0717882D0 (en) | Novel pharmaceutical | |
| IL219623A0 (en) | [1,5]-diazocin derivatives | |
| EP2236135A4 (en) | STABLE PHARMACEUTICAL COMPOSITION | |
| GB0813815D0 (en) | Corcost Pre 1001,10 | |
| GB0808811D0 (en) | Algabe 2.1 |